Cargando…

Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study

CONTEXT: Clinical study for immunity. AIMS: The present study aimed to assess the effect of proprietary polyherbal formulation (PPHF), labelled as Kofol immunity tablets (KIT) on innate and adaptive immune responses in healthy individuals, on the backdrop of COVID-19 pandemic. SETTINGS AND DESIGN: S...

Descripción completa

Detalles Bibliográficos
Autores principales: Khadke, Suresh, Gupte, Poonam, Mourya, Akanksha, Yadav, Amit, Mane, Sarika, Joshi, Asavari, Mahajan, Madhavi, Mishra, Manisha, Bhalerao, Supriya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405535/
https://www.ncbi.nlm.nih.gov/pubmed/37554241
http://dx.doi.org/10.4103/picr.picr_100_22
_version_ 1785085553348182016
author Khadke, Suresh
Gupte, Poonam
Mourya, Akanksha
Yadav, Amit
Mane, Sarika
Joshi, Asavari
Mahajan, Madhavi
Mishra, Manisha
Bhalerao, Supriya
author_facet Khadke, Suresh
Gupte, Poonam
Mourya, Akanksha
Yadav, Amit
Mane, Sarika
Joshi, Asavari
Mahajan, Madhavi
Mishra, Manisha
Bhalerao, Supriya
author_sort Khadke, Suresh
collection PubMed
description CONTEXT: Clinical study for immunity. AIMS: The present study aimed to assess the effect of proprietary polyherbal formulation (PPHF), labelled as Kofol immunity tablets (KIT) on innate and adaptive immune responses in healthy individuals, on the backdrop of COVID-19 pandemic. SETTINGS AND DESIGN: Single-blind, randomized, placebo-controlled, exploratory study in institutional setting. MATERIALS AND METHODS: Post Ethics Committee permission, screened healthy individuals of either sex aged 18–35 years were randomized to PPHF/Placebo for 2 months. Major assessment variables included peak expiratory flow rate (PEFR), questionnaire-based immune status, perceived stress, and quality of life (QOL) with immune-specific cell counts (CD4+, CD8+), cytokines (interferon gamma [IFN-γ], tumor necrosis factor-alpha [TNF-α], interleukin 10 [IL-10]), and oxidative stress in red blood cells (RBCs) (malondialdehyde (MDA), glutathione peroxidase [GPx]), done at day 60. STATISTICAL ANALYSIS USED: Mean ± standard deviation and paired/unpaired t-test for parametric data analysis while median (range) and Wilcoxon Rank sum test/Mann–Whitney test for nonparametric data analysis, were done. Categorical data was analyzed using Chi-square test. GraphPad InStat software, version 9 was used with p < 0.05, as the level of statistical significance. RESULTS: Of 52 recruited, 28 individuals completed the study. PPHF significantly increased PEFR, improved immune status along with QOL compared to baseline. It also decreased perceived stress from moderate and severe grade to mild. Serum IFN-γ levels remained almost constant post-PPHF treatment. PPHF significantly decreased MDA and increased GPx in RBCs. Significant decrease and increase in TNF-α and IL-10, respectively, were seen in PPHF group. The safety parameters post-PPHF treatment remained within normal reference ranges. CONCLUSIONS: PPHF is an efficacious and safe formulation with immunomodulatory potential.
format Online
Article
Text
id pubmed-10405535
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-104055352023-08-08 Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study Khadke, Suresh Gupte, Poonam Mourya, Akanksha Yadav, Amit Mane, Sarika Joshi, Asavari Mahajan, Madhavi Mishra, Manisha Bhalerao, Supriya Perspect Clin Res Original Article CONTEXT: Clinical study for immunity. AIMS: The present study aimed to assess the effect of proprietary polyherbal formulation (PPHF), labelled as Kofol immunity tablets (KIT) on innate and adaptive immune responses in healthy individuals, on the backdrop of COVID-19 pandemic. SETTINGS AND DESIGN: Single-blind, randomized, placebo-controlled, exploratory study in institutional setting. MATERIALS AND METHODS: Post Ethics Committee permission, screened healthy individuals of either sex aged 18–35 years were randomized to PPHF/Placebo for 2 months. Major assessment variables included peak expiratory flow rate (PEFR), questionnaire-based immune status, perceived stress, and quality of life (QOL) with immune-specific cell counts (CD4+, CD8+), cytokines (interferon gamma [IFN-γ], tumor necrosis factor-alpha [TNF-α], interleukin 10 [IL-10]), and oxidative stress in red blood cells (RBCs) (malondialdehyde (MDA), glutathione peroxidase [GPx]), done at day 60. STATISTICAL ANALYSIS USED: Mean ± standard deviation and paired/unpaired t-test for parametric data analysis while median (range) and Wilcoxon Rank sum test/Mann–Whitney test for nonparametric data analysis, were done. Categorical data was analyzed using Chi-square test. GraphPad InStat software, version 9 was used with p < 0.05, as the level of statistical significance. RESULTS: Of 52 recruited, 28 individuals completed the study. PPHF significantly increased PEFR, improved immune status along with QOL compared to baseline. It also decreased perceived stress from moderate and severe grade to mild. Serum IFN-γ levels remained almost constant post-PPHF treatment. PPHF significantly decreased MDA and increased GPx in RBCs. Significant decrease and increase in TNF-α and IL-10, respectively, were seen in PPHF group. The safety parameters post-PPHF treatment remained within normal reference ranges. CONCLUSIONS: PPHF is an efficacious and safe formulation with immunomodulatory potential. Wolters Kluwer - Medknow 2023 2023-05-22 /pmc/articles/PMC10405535/ /pubmed/37554241 http://dx.doi.org/10.4103/picr.picr_100_22 Text en Copyright: © 2023 Perspectives in Clinical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Khadke, Suresh
Gupte, Poonam
Mourya, Akanksha
Yadav, Amit
Mane, Sarika
Joshi, Asavari
Mahajan, Madhavi
Mishra, Manisha
Bhalerao, Supriya
Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study
title Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study
title_full Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study
title_fullStr Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study
title_full_unstemmed Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study
title_short Immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: A single- blind, randomized, placebo- controlled, exploratory clinical study
title_sort immunomodulatory effect of a proprietary polyherbal formulation on healthy participants: a single- blind, randomized, placebo- controlled, exploratory clinical study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405535/
https://www.ncbi.nlm.nih.gov/pubmed/37554241
http://dx.doi.org/10.4103/picr.picr_100_22
work_keys_str_mv AT khadkesuresh immunomodulatoryeffectofaproprietarypolyherbalformulationonhealthyparticipantsasingleblindrandomizedplacebocontrolledexploratoryclinicalstudy
AT guptepoonam immunomodulatoryeffectofaproprietarypolyherbalformulationonhealthyparticipantsasingleblindrandomizedplacebocontrolledexploratoryclinicalstudy
AT mouryaakanksha immunomodulatoryeffectofaproprietarypolyherbalformulationonhealthyparticipantsasingleblindrandomizedplacebocontrolledexploratoryclinicalstudy
AT yadavamit immunomodulatoryeffectofaproprietarypolyherbalformulationonhealthyparticipantsasingleblindrandomizedplacebocontrolledexploratoryclinicalstudy
AT manesarika immunomodulatoryeffectofaproprietarypolyherbalformulationonhealthyparticipantsasingleblindrandomizedplacebocontrolledexploratoryclinicalstudy
AT joshiasavari immunomodulatoryeffectofaproprietarypolyherbalformulationonhealthyparticipantsasingleblindrandomizedplacebocontrolledexploratoryclinicalstudy
AT mahajanmadhavi immunomodulatoryeffectofaproprietarypolyherbalformulationonhealthyparticipantsasingleblindrandomizedplacebocontrolledexploratoryclinicalstudy
AT mishramanisha immunomodulatoryeffectofaproprietarypolyherbalformulationonhealthyparticipantsasingleblindrandomizedplacebocontrolledexploratoryclinicalstudy
AT bhaleraosupriya immunomodulatoryeffectofaproprietarypolyherbalformulationonhealthyparticipantsasingleblindrandomizedplacebocontrolledexploratoryclinicalstudy